查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041578

全球CAR-T細胞療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global CAR T Cell Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 153 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球CAR-T細胞療法市場預計將從2025年的62.5億美元成長至2034年的187.9億美元，2026年至2034年的複合年成長率（CAGR）為13.02%。該市場正經歷快速擴張，這主要得益於先進免疫療法在癌症治療中的日益普及。 CAR-T細胞療法正成為治療某些血液癌症的突破性方法，與傳統治療方法相比，有望提高患者的存活率。生物技術研究和臨床試驗投入的增加顯著推動了市場成長。此外，醫療專業人員和患者對創新癌症治療方法的認知不斷提高，也加劇了對個人化治療方案的需求。

全球癌症發生率的不斷上升仍然是市場發展的主要驅動力。製藥公司和研究機構正大力投資開發新的治療方法並提高治療效果。創新治療方法的監管核准也促進了其在醫療保健系統中的廣泛應用。此外，基因工程和細胞處理技術的進步正在提高治療成功率，並支持專業癌症治療中心的持續擴張。

前景十分光明，因為持續的研究正在探索新的治療適應症並改進生產方法。經濟高效的生產技術的開發有望使更多患者獲得治療。醫療基礎設施的擴建和腫瘤研究經費的增加可望支持永續成長。此外，生技公司與醫療機構之間的合作有望加速創新，並加強這一快速發展治療領域的長期發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為了解競爭趨勢和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球CAR-T細胞療法市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 異丁二烯矽醇（傑斯卡特）
  • Brexkabutagene autreucer (Tekartus)
  • Siltacaptadiene autoleucel（Carvykti）
  • Idekabutadiene Vikrulcel (Avekma)
  • Lyzocabutadiene Malaloyl (Breyanzi)
  • Tisagenreclersel (Kymriah)
  • 其他

第5章 全球CAR-T細胞療法市場：依適應症分類

  • 市場分析、洞察與預測
  • 急性淋巴性白血病
  • 非何傑金氏淋巴瘤
  • 多發性骨髓瘤

第6章 全球CAR-T細胞療法市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 腫瘤治療中心

第7章 全球CAR-T細胞療法市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Gilead Sciences Inc.（US）
    • Novartis AG（Switzerland）
    • Bristol-Myers Squibb Company（US）
    • Johnson & Johnson Services Inc.（Janssen Global Services LLC）（US）
    • Caribou Biosciences Inc.（US）
    • CARsgen Therapeutics Co. Ltd（China）
    • JW Therapeutics（Shanghai）Co. Ltd.（China）
    • Cartesian Therapeutics Inc.（US）
    • Aurora Biopharma
簡介目錄
Product Code: VMR11210077

The global CAR T cell therapy market size is expected to reach USD 18.79 Billion in 2034 from USD 6.25 Billion in 2025, growing at a CAGR of 13.02 during 2026-2034.This market has witnessed rapid expansion due to increasing adoption of advanced immunotherapy treatments for cancer management. CAR T cell therapy has emerged as a breakthrough approach for treating certain blood cancers, offering improved survival outcomes compared to conventional treatments. Growing investments in biotechnology research and clinical trials have significantly supported market growth. Additionally, rising awareness among healthcare providers and patients regarding innovative cancer therapies has strengthened demand for personalized treatment solutions.

Increasing prevalence of cancer worldwide remains a major factor driving market development. Pharmaceutical companies and research institutions are investing heavily in developing new therapeutic applications and improving treatment efficiency. Regulatory approvals for innovative therapies have also encouraged broader adoption across healthcare systems. Furthermore, advancements in genetic engineering and cell processing technologies have enhanced treatment success rates, supporting continued expansion across specialized oncology treatment centers.

Future prospects appear highly promising as ongoing research continues to explore new therapeutic indications and improved manufacturing methods. Development of cost-effective production techniques is expected to improve treatment accessibility across broader patient populations. Expansion of healthcare infrastructure and increased funding for oncology research are likely to support sustained growth. Additionally, collaborations between biotechnology firms and healthcare providers are anticipated to accelerate innovation, strengthening long-term development in this rapidly evolving therapeutic field.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

COMPANIES PROFILED

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CAR T CELL THERAPY MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Type
  • 4.2. Axicabtagene Ciloleucel (Yescarta) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Brexucabtagene Autoleucel (Tecartus) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Ciltacabtagene Autoleucel (Carvykti) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Idecabtagene Vicleucel (Abecma) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Lisocabtagene Maraleucel (Breyanzi) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Tisagenlecleucel (Kymriah) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CAR T CELL THERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Indication
  • 5.2. Acute Lymphoblastic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Non-Hodgkin Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CAR T CELL THERAPY MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oncology Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CAR T CELL THERAPY MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Type
    • 7.2.2 By Indication
    • 7.2.3 By End-user
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Type
    • 7.3.2 By Indication
    • 7.3.3 By End-user
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Type
    • 7.4.2 By Indication
    • 7.4.3 By End-user
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Type
    • 7.5.2 By Indication
    • 7.5.3 By End-user
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Type
    • 7.6.2 By Indication
    • 7.6.3 By End-user
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CAR T CELL THERAPY INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Gilead Sciences Inc. (U.S.)
    • 9.2.2 Novartis AG (Switzerland)
    • 9.2.3 Bristol-Myers Squibb Company (U.S.)
    • 9.2.4 Johnson & Johnson Services Inc. (Janssen Global Services LLC) (U.S.)
    • 9.2.5 Caribou Biosciences Inc. (U.S.)
    • 9.2.6 CARsgen Therapeutics Co. Ltd (China)
    • 9.2.7 JW Therapeutics (Shanghai) Co. Ltd. (China)
    • 9.2.8 Cartesian Therapeutics Inc. (U.S.)
    • 9.2.9 Aurora Biopharma